Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists

Patent metadata

Field	Value
Publication number	US-11274105-B2
Application number	US-201916977527-A
Country	US
Kind code	B2
Filing date	Mar 4, 2019
Priority date	Mar 5, 2018
Publication date	Mar 15, 2022
Grant date	Mar 15, 2022

Abstract

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

First claim

What is claimed:

1. A compound of Formula I:

a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof,
wherein:
b, represented by the symbol , is a single or double chemical bond which may be cis or trans,
Z is selected from C or N;
R 1 is independently selected from H, —C 1-6 haloalkyl, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —(CH 2 CH 2 O) n R a , —C(═O)R a , —C(═O)OR a , —C(═O)NR a R b , —C 1-6 alkyl-O-C 1-6 alkyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 ;
R 1A is H;
each of R 6 , R 8 , R 2A , R 3A , and R 8A is independently selected from H, halo, —C 1-6 haloalkyl, —C 1-6 alkyl, —O—C 1-6 alkyl, —C 2-6 alkenyl, —C 1-6 alkyl-O-C 1-6 alkyl, —(CH 2 CH 2 O) n R a , —SO 2 R a , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —C(═O)NR a R b , a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 and further wherein R 8 and R 8A may also be OH;
R 2 is H;
R 3 is H;
R 4 is H or C 1-6 alkyl;
R 4A is H;
R 5 is H or C 1-6 alkyl;
R 5A is H;
R 7 is H or C 1-6 alkyl;
R 7A is H;
R 9 is H;
R 10 is halo;
when b is a double bond, R 2A and R 3A are absent;
wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycloalkyl and spiroheterocycloalkyl groups of the R 1 substituent can be unsubstituted or substituted with 1, 2, 3 or 4 R 11 substituents independently selected from OH, halo, —NR c R d , —C 1-6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —OC 1-6 alkyl, —C 1-6 alkyl-OH, —C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, —O-haloC 1-6 alkyl, —SO 2 R c , —CN, —C(═O)NR c R d , —C(═O)R c , —OC(═O)R a , —C(═O)OR c , a 6- to 12-membered aryl, a 6- to 12-membered heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups have 0, 1, 2, 3 or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 ;
wherein the —C 1-6 alkyl of any of the R 1 , R 6 , R 8 , R 11 , R 2A , R 3A , and R 8A substituents is unsubstituted or substituted by 1, 2 or 3 R 12 substituents independently selected from OH, —OC 1-6 alkyl, —C 1-6 alkyl-O-C 1-6 alkyl, halo, —O-haloC 1-6 alkyl, —CN, —NR a R b , —(NR a R b R c ) n , —SO 2 R a , —(CH 2 CH 2 O) n CH 3 , (═O), —C(═O)R a , —OC(═O)R a , —C(═O)OR a , —C(═O)NR a R b , —O—SiR a R b R c , —O-(3- to 12-membered heterocycloalkyl), phenyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 ;
wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycloalkyl and spiroheterocycloalkyl groups of any of the R 6 , R 8 , R 11 and R 12 substituents can be unsubstituted or substituted with 1, 2, 3 or 4 R 13 substituents independently selected from OH, halo, —C 1-6 alkyl, —OC 1-6 alkyl, —C 1-6 alkyl-OH, —C 1-6 alkyl-O-C 1-6 alkyl, C 1-6 haloalkyl, —O-haloC 1-6 alkyl, —SO 2 R c , —NR c R d , —CN, —C(═O)NR c R d , —C(═O)R c , —OC(═O)R a , —C(═O)OR c , —B(OH) 2 , a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 ;
wherein each R a , R b , R c , and R d is independently H, OH, —C 1-6 alkyl, —C 1-6 alkenyl, —C 2-6 alkynyl, —C 1-6 alkyl-NR 14 R 14 , NR 14 R 14 , —SO 2 R 14 , —(CH 2 CH 2 O) n CH 3 , —C(═O)R 14 , —OC(═O)R 14 , —C(═O)OR 14 , —C(═O)NR 14 R 14 , C 1-6 haloalkyl, —O-haloC 1-6 alkyl, —C 1-6 alkyl-O-C 1-6 alkyl, —C 1-6 alkyl-OH, benzyl, phenyl, a —C 1-6 alkyl-3- to 12-membered heterocycloalkyl, a 6- to 12-membered aryl or heteroaryl, a 5- to 12-membered spirocycloalkyl or spiroheterocycloalkyl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, and heterocycloalkyl groups and the heterocycloalkyl group of the —C 1-6 alkyl-heterocycloalkyl group have 1, 2, 3, or 4 heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, heterocycloalkyl, and the heterocycloalkyl groups of the —C 1-6 alkyl-heterocycloalkyl group may include a C═O group, and further wherein the spiroheterocycloalkyl and heterocycloalkyl groups may include a S═O or SO 2 ;
wherein R 14 substituents are independently selected from H, —OH, halo, —C 1-6 alkyl, —OC 1-6 alkyl, —C 1-6 alkyl-OC 1-6 alkyl, —C 1-6 haloalkyl, —O-haloC 1-6 alkyl, phenyl, tolyl, —C(O)C 1-6 alkyl, —C(O)OCH 3 , —SO 2 -phenyl, —SO 2 —N(CH 3 ) 2 , —N═N═N, —NH 2 , —N(C 1-6 alkyl) 2 , —NR 15 C 1-6 alkyl, —NR 15 C 1-6 alkyl-O-C 1-6 alkyl, —N(C 1-6 alkyl)C 1-6 alkyl-O-C 1-6 alkyl, —NR 15 —C 1-6 alkyl-3- to 12-membered heterocycloalkyl, a NR 15 -6- to 12-membered aryl or heteroaryl, a NR 15 -3- to 12-membered cycloalkenyl, a NR 15 -3- to 12-membered monocyclic or bicyclic cycloalkyl, or a NR 15 -3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, a —C 1-6 alkyl-3- to 12-membered heterocycloalkyl, a 6- to 12-membered aryl or heteroaryl, a 3- to 12-membered cycloalkenyl, a 3- to 12-membered monocyclic or bicyclic cycloalkyl, or a 3- to 12-membered monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, and heterocycloalkyl groups and the heterocycloalkyl group of the —C 1-6 alkyl-heterocycloalkyl group have 1,

Assignees

• Amgen Inc

Inventors

• Rescourio Gwenaella
• Gonzalez Buenrostro Ana
• Brown Sean P
• Lizarzaburu Mike
• Medina Julio
• Jabri Salman Yojiro
• Sun Daqing
• Simonovich Scott Preston
• Yan Xuelei
• Li Yihong
• Rew Yosup

Classifications

• C07D498/22

  in which the condensed system contains four or more hetero rings · CPC title

• C07D498/10 Primary

  Spiro-condensed systems · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title